Cytokine secretion and NK cell activity in human ADAM17 deficiency

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44151-44160

  Tsukerman, Pinchas ^a   Eisenstein, Eli M ^b   Chavkin, Maor ^b   Schmiedel, Dominik ^a   Wong, Eitan ^c   Werner, Marion ^b   Yaacov, Barak ^b   Averbuch, Diana ^b   Molho Pessach, Vered ^b   Stepensky, Polina ^b   Kaynan, Noa ^a   Bar On, Yotam ^a   Seidel, Einat ^a   Yamin, Rachel ^a   Sagi, Irit ^c   Elpeleg, Orly ^b   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

ADAM17 deficiency; ADCC; CD16; Immune response; Immunity; Immunology and microbiology section; NK cells

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; CD16 ANTIGEN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CYTOKINE; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CASE REPORT; CHILD; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; INFANT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; RECURRENT INFECTION; RESPIRATORY FAILURE; SEPSIS; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; FATALITY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MONONUCLEAR CELL; PHENOTYPE; TUMOR CELL LINE;

ADAM PROTEINS; ADAM17 PROTEIN; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CHILD, PRESCHOOL; CYTOKINES; FATAL OUTCOME; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC DEFICIENCY SYNDROMES; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; PHENOTYPE; RECEPTORS, IGG;

EID: 84953455856     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6629     Document Type: Article

References (24)

1. Koch J, Steinle A, Watzl C and Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013; 34(4):182-191.
2. Raulet DH and Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol. 2009; 9:568-580.
3. Caligiuri MA. Human natural killer cells. Blood. 2008; 112:461-469.
4. Seidel E, Glasner A and Mandelboim O. Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci. 2012; 69:3911-20.
5. Long EO, Kim HS, Liu D, Peterson ME and Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013; 31:227-258.
6. Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, Del Zotto G, Locatelli F, Moretta A and Mingari MC. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front Immunol. 2014; 5:87.
7. Bryceson YT, March ME, Ljunggren HG and Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006; 107:159-166.
8. Lanier LL, Ruitenberg JJ and Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol. 1988; 141:3478-3485.
9. Lanier LL, Yu G and Phillips JH. Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature. 1989; 342:803-805.
10. Wirthmueller U, Kurosaki T, Murakami MS and Ravetch JV. Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J Exp Med. 1992; 175:1381-1390.
11. Scheller J, Chalaris A, Garbers C and Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011; 32:380-387.
12. Khokha R, Murthy A and Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol. 2013; 13:649-665.
13. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B and Miller J. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013; 121:3599-3608.
14. Chalaris A, Adam N, Sina C, Rosenstiel P, Lehmann-Koch J, Schirmacher P, Hartmann D, Cichy J, Gavrilova O, Schreiber S, Jostock T, Matthews V, Hasler R, Becker C, Neurath MF, Reiss K, et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med. 2010; 207:1617-1624.
15. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf F, Toynbee M, Walne A, O'Toole EA, Martin JE, Lindley K, Vulliamy T, Abrams DJ, MacDonald TT, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011; 365:1502-1508.
16. Ta-Shma A, Perles Z, Yaacov B, Werner M, Frumkin A, Rein AJ and Elpeleg O. A human laterality disorder associated with a homozygous WDR16 deletion. Eur J Hum Genet. 2015; 23:1262-5.
17. Lajoie L, Congy-Jolivet N, Bolzec A, Gouilleux-Gruart V, Sicard E, Sung HC, Peiretti F, Moreau T, Vie H, Clemenceau B and Thibault G. ADAM17-mediated shedding of FcgammaRIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol. 2014; 192:741-751.
18. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, Pandey R, Campbell KS and Orange JS. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest. 2012; 122:3769-3780.
19. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE and Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A. 1999; 96:5640-5644.
20. Maretzky T, Zhou W, Huang XY and Blobel CP. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. Oncogene. 2011; 30:611-618.
21. Tortorella MD, Tomasselli AG, Mathis KJ, Schnute ME, Woodard SS, Munie G, Williams JM, Caspers N, Wittwer AJ, Malfait AM and Shieh HS. Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. J Biol Chem. 2009; 284:24185-24191.
22. Scott AM, Wolchok JD and Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12:278-287.
23. Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA and Miller JS. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013; 19:3844-3855.
24. Tsukerman P, Stern-Ginossar N, Yamin R, Ophir Y, Stanietsky AM and Mandelboim O. Expansion of CD16 positive and negative human NK cells in response to tumor stimulation. Eur J Immunol. 2014; 44:1517-1525.